Insulin therapy is the most effective method of lowering blood glucose. Over 100 years have passed the studies for the optimisation of insulin action. To date, subcutaneous insulin administration has been the basic route of insulin delivery. The search for insulin therapy is simultaneously conducted in the following directions: the optimisation of insulin action, automatisation, and the decrease in the invasiveness of insulin delivery methods. The optimisation of insulin action has led to the discovery of ultra-rapid-acting human insulin analogues, ultra-long-acting human insulin analogues, and biosimilar insulin. Automatisation referred to the "artificial pancreas" and closing the loop system in insulin pump therapy. The decrease in the invasiveness of insulin delivery methods is focused on alternative routes of insulin administration. 
Introduction
Insulin therapy is the most effective method of lowering blood glucose. It is absolutely essential in the treatment of Type 1 diabetes mellitus (T1DM) and indispensable in many cases of Type 2 diabetes mellitus (T2DM). Over 100 years have passed since the discovery and the first use of insulin. A number of studies have been conducted, the aim of which was to mimic a physiological response to the increase in glycaemia and to optimise insulin therapy. These studies have allowed the use of human insulin on a large scale and then rapid-acting and long-acting human insulin analogues. To date, subcutaneous insulin administration with pens and insulin pumps has been the basic route of insulin delivery [1] . Fast-acting insulin may also be given intravenously, particularly in hospitalised patients in considerable hyperglycaemia, such as ketoacidosis, hyperglycaemichypermolar syndromes, or in the treatment of carbohydrate disorders in patients in intensive care units and in the perioperative period in surgical units [2] . There have also been trials to administer insulin intravenously in patients with diabetic senso-motoric analgesic polyneuropathy in order to alleviate pain intensity and to improve the quality of life of diabetic patients [3] .
Together with technological progress and the advancement of diabetes-related knowledge, the studies and the search for insulin therapy are simultaneously being conducted in the following directions: -the optimisation of insulin action by pharmacokinetic modifications (ultra-rapid-acting human insulin analogues, ultra-long-acting human insulin analogues, or the use of components accelerating the absorption such as warming the injection site, adding recombinant human hyaluronidase, or intradermal insulin delivery). -automatisation (i.e. insulin pump therapy in the closed loop system, referred to as the "artificial pancreas"). 
Optimisation of insulin action
Under physiological conditions, there are two ways of insulin secretion -the first one is meal-related response and the second is a basic way that is independent of meals and is secreted in pulses. Insulin is delivered into the portal vein and ~50% of insulin there is distributed into peripheral tissues. Exogenous administration of insulin cannot fully mimic a physiological character of insulin secretion because it is delivered into peripheral tissues, which adversely affects liver function in terms of carbohydrate metabolism in patients with endogenous insulin deficiency. Both pharmacodynamic characteristics of formulations and the mode of delivery influence their dynamics of action.
Rapid-acting insulin
Rapid-acting insulin analogues have been available on the market since 1996. However, their peak of action is still insufficient and does not fully cover postprandial hyperglycaemia.
There are several methods to accelerate the absorption and to improve the action of insulin under research.
The ultra-rapid human insulin VIAject (Linjeta). Test results indicate that it has a faster onset of action as compared to Lispro analogue and human insulins used so far, which is reflected by a more effective decrease in postprandial glycaemia without an increased risk of hypoglycaemia. Linjeta is a formulation containing short-acting human insulin, EDTA, and citric acid. These components result in hexameric insulin dissociation into insulin monomers and a more rapid insulin absorption [4, 5] .
Comparing the influence of Linjeta, Lispro, and fast-acting human insulin on postprandial glycaemia in patients with Type 1 diabetes, significantly lower values were obtained in the Linkjeta group (0-180 min; 157 ± 30 mg/dL; p = 0.002 vs. fast-acting human insulin) and in the Lispro group (170 ± 42 mg/dL; p = 0.668 vs. fast-acting human insulin). The difference between maximal and minimal glycaemia was lower in the case of Linjeta and was 70 ± 17 mg/dL, as compared to fast-acting human insulin (91 ± 33 mg/dL; p = 0.007 vs. Linjeta) and Lispro (89 ± 18 mg/dL; p = 0.011 vs. Linjeta) [4] .
Different methods have been used to accelerate insulin absorption. Clinical trials have been conducted with an InsuPatch device heating the injection site and increasing blood supply, which resulted in more rapid insulin absorption. This device might be integrated with an insulin pump thus improving the functioning of the pump [6] [7] [8] .
Addition of recombinant human hyaluronidase to insulin formulation is yet another method to accelerate the absorption and action of insulin. Study results confirm the acceleration of insulin absorption from the injection site and a faster onset of its action, which results in the improvement in postprandial glycaemic control without an increased risk of hypoglycaemia. These results also indicate good tolerance and safety of the method [9] .
Intradermal administration of insulin using a 0.9 mm-long microneedle also accelerates insulin absorption. In two clinical studies on patients at different ages a more rapid onset of action (of ~22 min) was observed as compared to subcutaneous insulin administration. This is due to a more rapid absorption of insulin from the stratum papillare, which is rich in lymphatic vascularity and is well supplied with blood [10] . It offers some hope for the improvement in the precision of insulin pump therapy in the closed loop system. Intradermal insulin delivery was not more painful compared to subcutaneous administration, as assessed by patients in the visual analogue pain scale (VAS) [10] .
New basal insulin
Degludec A medical need remains for a once-daily insulin with 24-hour basal coverage in all diabetic patients. The search for the improvement in pharmacodynamic properties of insulin has resulted in introducing insulin Degludec, which is an ultra-long-acting basal insulin analogue. In January 2013 the European Medicines Agency granted a marketing authorisation and approved Tresiba (insulin Degludec) and Ryzodeg (insulin Degludec and rapid-acting analogue of human insulin Aspart) for distribution in the European Union [11] .
After subcutaneous injection Degludec creates soluble multi-hexamers from which it is slowly absorbed into the bloodstream. Time of action is over 42 hours for therapeutic doses. The balance is obtained after 2-3 days of administration. A total decrease in glucose level after Degludec administration increases linearly with dose increase [12] . Eleven treat-to-target international, controlled, open, randomised trials were conducted with the parallel groups. These trials lasted 26 or 52 weeks. A total of 4275 patients were administered Degludec (1102 with T1DM and 3173 with T2DM). It was confirmed that a decrease in HbA 1c was the same in all trials in terms of all the compared products (insulin Detemir and insulin Glargine) [12] [13] [14] .
In the meta-analysis including seven treat-to-target trials Degludec was demonstrated to be more effective
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as regards a lower number of confirmed treatment-related hypoglycaemic episodes and nocturnal confirmed hypoglycaemia, as compared to basal insulin Glargine in patients with Type 1 and 2 diabetes. The decrease in hypoglycaemia was achieved with a lower mean plasma glucose level during the administration of Degludec compared to the administration of insulin Glargine [15] .
The mixed formulation of insulin Degludec and insulin Aspart administered in T1DM at mealtime resulted in a decrease in HbA1c by 0.7%, and in patients with T2DM even by as much as 1.7% when it was administered alone or in combination with other antidiabetic agents [16] [17] .
Glargine U300 Using higher concentration insulin was another method to prolong its action. Glargine U300 was characterised by a significantly longer action compared to classic Glargine U100 and was related to lower variability of serum concentrations. It was demonstrated that the action of Glargine U300 lasts up to 36 hours after subcutaneous injection. A more stable release of insulin glargine U300 as compared to insulin Glargine U100 is related to the decrease in the volume of injection by 2/3, which results in a lower precipitate surface [18] .
Similar efficacy and safety profile were obtained when Glargine U100 and U300 were compared. However, a lower weight gain and a lower risk of hypoglycaemia were observed in a group of patients using Glargine U300 [19] .
PEGylated insulin Lispro
Next to insulin Degludec and Glargine U300, PEGylated insulin Lispro also deserves attention. It is formed by attaching a polyethylene glycol chain to the particle of insulin Lispro. The aim of PEGylation is to prolong the action of the insulin particle, to increase its hydrodynamic abilities, and to slow down subcutaneous absorption [20] . Insulin modified in such a way is characterised by a 24-hour flat profile of action. It shows more hepatic rather than peripheral activity, thereby mimicking endogenous insulin. Clinical studies revealed a similar or even better glycaemic control in patients using PegLispro as compared to Glargine. Lower glycaemic variability was noted both in T1DM and T2DM with a beneficial influence on body mass -a loss of up to 5% of body mass in the group of patients treated with PegLispro. The risk of nocturnal hypoglycaemia was significantly lower with a slightly increased risk of hypoglycaemia in general (NS). There was no need for dose modification in patients with renal problems [20] . In phase 3 trials, compared to insulin Glargine, PegLispro demonstrated a better influence on glycaemic control, lower glycaemic variability, and a reduction in a total number of hypoglycaemia, especially nocturnal hypoglycaemia. However, an increase in triglycerides, elevated liver enzymes, and increased fat content in the liver were reported [21] . The above observations resulted in termination of further trials concerning PEGylated insulin Lispro, and in December 2015 EliLilly stopped further observations.
Biosimilar insulin
The sale of insulin increases every year, hence the greater interest of pharmaceutical companies in introducing biosimilar insulins onto the market. It is a well-known fact that protein (i.e. insulin) production covers a few stages, and even small changes in the complex procedure may result in the production of protein products that are different from the original. Eli Lilly and Merck conduct independent clinical research using biosimilar Glargine [22] .
Biodel Inc., a pharmaceutical company, is working on another basal insulin -referred to as BIODregulated basal insulin that contains modified insulin Glargine and possesses the ability to mix formulations of different time of action [22] .
BIOD-Smart Basal is another promising formulation that was also offered by Biodel. It contains insulin Glargine, glucose oxidase, and peroxidase. In the presence of glucose and the above enzymes, gluconic acid is formed. It lowers pH of the suspension and increases solubility of insulin Glargine, thus promoting its release into the bloodstream.
The idea of "smart insulin" cannot be omitted. As part of the research on technology platforms (SmartCells), scientists from the Massachusetts Institute of Technology were the first to put forward the idea that an insulin particle could to be modified so that it could be activated by sufficiently high blood glucose concentration. This research, however, is still in the preclinical phase [22] .
After completing the necessary research and obtaining the approval of the European Medicines Agency, Eli Lilly started production and sales of biosimilar insulin Glargine in Europe ( LY2963016 ). Since 2015 biosimilar Glargine (trade name Abasaglar) has also been available in Poland [23, 24] .
Automatisation

Artificial pancreas
The first insulin pumps and the devices for continuous glycaemic monitoring appeared as early as in the 1960s. Since that time there have been trials to "close the loop", i.e. to create a system in which the information on glycaemic level could automatically influence insulin delivery [25] .
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In 1964 Dr Arnold Kadish was the first scientist who managed to connect the pump and a sensor with a simple system opening and closing the flow of insulin based on glycaemic measurements. In the 1970s systems using microcomputers were created. They calculated the demand for insulin by means of a simple algorithm. However, due to the bulky size of these devices, they could be used only at the bedside. In the 1980s the first portable devices appeared on the market [26] . Despite the fact that currently the size of the pumps is relatively small, the key problem that limits their broad clinical usage is still the need for improvement in glucose sensors due to the delay period concerning the information and the delay in insulin delivery and in the onset of its action.
A number of professionals, including physicians, mathematicians, computer scientists, and algorithm specialists are involved in the teamwork on algorithms. The most advanced predictive-control algorithms plan the action a few moves ahead.
Constant progress in improving sensors as well as the efforts made to accelerate the onset of insulin action by adding recombinant human hyaluronidase, warming the site of injection, intradermal delivery, and the use of ultra-fast-acting insulin contribute to the reduction in postprandial glycaemia and lead to the desired efficacy and the closure of the loop system. An adequate reaction to dynamic glycaemic changes induced by meals and physical activity poses a real challenge to the artificial pancreas. A slightly easier role of the artificial pancreas seems to be at night, which is confirmed in the case of pumps that automatically suspend insulin delivery and are already available on the market [26, 27] .
Bihormonal pump
The practical use of a bihormonal pump (insulin+ + glucagon) is a subject of conducted research in patients with T1DM. A pilot study on six patients with T1DM was performed. The subjects were monitored for over 48 hours with special attention paid to the efficacy and safety of the bihormonal pump in normal life (consumption of at least six carbohydrate-rich meals and physical activity). Glycaemia was measured every 15 minutes. The study results seem to be promising. Due to the pump, patients reached good glycaemic control with the minimal number of hypoglycaemic episodes (the lowest registered glycaemic value was 62 mg/dL) [28] . In 2014 another trial was conducted with a higher number of patients, i.e. 20 adults and 32 teenagers with type 1 diabetes, in whom the fully autonomic bionic pancreas was used. Glycaemic control, insulin, and glucagon administration were done in a completely automatic manner, based on a mathematical algorithm recorded on a smartphone, with consideration given to the results of CGMS (continuous glucose monitoring system) -Dexcom. The mean glycaemic control level was obtained, i.e. 138 mg/dL, and glycaemic level was noted within 4.8% and 6.1% of the time in adults and teenagers, respectively. Unlike previous studies, patients were allowed to consume meals and undertake physical activity at any time [ 29] . The greatest barrier with using bihormonal pumps is still the lack of a precise algorithm and the imperfection of continuous glucose monitoring systems. However, the computer progress, miniaturisation of electronic technology, and the use of modern smartphones to control the artificial pancreas gives hope to a great number of patients with type 1 diabetes.
Alternative routes of insulin administration
Inhaled insulin
Despite advanced technology and promising study results (though often in the pre-clinical phase), a change in the route of insulin administration has not been successful in clinical practice. Negative marketing experience with Exubera, the first inhalable insulin, resulted in great caution to such novelties. Exubera was given marketing authorisation for a medicinal product in the European Union in 2006. However, it was withdrawn from the market after a few months, which resulted in enormous financial losses. The reason for the withdrawal was related to poor sales results, which were caused by too high a price, a bulky size of the inhaler, dose-related problems, limitations of use in the case pulmonary diseases, lack of reports on long-term results and safety, as well as complications in the form of cough.
However, attempts to use this route for periprandial insulin administration were not abandoned due to very satisfactory conditions for inhaled drug absorption (a large absorption surface and rich vascularity) [30] . In June 2014 the FDA approved Afrezza, an inhaled powder with fast-acting insulin in the form of technospheres (lyophilised microspheres made up of micromolecules of 2-3 µm). Technospheres are inhaled into the respiratory tract in the form of a dry powder. Afrezza is mainly addressed for periprandial use, with its onset of activity 15 minutes after inhalation. The inhaler is activated by the patient's breath. The efficacy of this form of insulin was confirmed in a number of clinical trials and studies, both in patients with type 1 diabetes combined with basal insulin as well as in patients with type 2 diabetes in conjunction with oral diabetic agents [31] . In phase 3 randomised clinical trials in patients with type 1 diabetes a lower reduction in HbA 1c was obtained in the group using Afrezza compared to the group using subcutaneous Aspart. However, significantly lower fasting glycaemic values, lower hypoglycaemia, and lower
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weight gain were obtained as compared to the Aspart in patients with type 2 diabetes [31] . HbA1c level was significantly higher in comparison the placebo group. Afrezza is contraindicated in patients with chronic pulmonary disease or asthma. The most frequent adverse effect is usually pain, pharyngeal irritation, or mild cough occurring within the first three months of therapy, which is not intensified over time [31] .
Transmucosal insulin
Transmucosal delivery is another means of non-invasive insulin delivery. An aerosol with properly adjusted nanoparticles is applied on the oral mucosa. Studies performed on animals offered promising results. Consequently, clinical trials were undertaken on healthy volunteers and patients with T1DM and T2DM. They showed that the absorption of insulin was more rapid in the form of an oral spray as compared to subcutaneous insulin delivery. Its onset of action was faster and the time of action was shorter [32] .
The rate of absorption depended on the dose administered. In general, it was well tolerated. The only adverse effect was transient mild nausea. The product is on the market in some countries (e.g. Ecuador, India). However, the possibility for clinical use is still distant in Europe and in the USA due to the lack of required clinical trials [32] .
Oral insulin
The possibility of oral insulin supplementation was an unattainable yet still very desired aim that has been pursued from the very beginning of insulin discovery [22] . In one study on patients with T1DM in whom an oral insulin preparation was used three times daily, 45 minutes before main meals with subcutaneous insulin administration for 15 days, a 24% reduction in the increase in glycaemic concentration above 200 mg/dL was noted. Furthermore, a greater reduction in glycaemic levels was observed in the morning hours, which is explained by hepatic pass of insulin and promoting the proper hepatic response concerning gluconeogenesis and glycogenolysis [33] .
The development of nanotechnology has offered some hope for an increase in the efficacy and the acceptance of oral route of insulin administration. Nanoparticles composed of biodegradable polymers (e.g. chitosan) transport drug particles protected against the gastric acid environment and digestive enzymes of the digestive tract. Nanoparticles allow mucoadherence and penetration through the mucous barrier of the digestive tract. Gradually, they release the active agent in a desired manner at the site from which it reaches the bloodstream. PEGylated calcium phosphate nanoparticles are considered the best carrier system for insulin.
IN-105 is an oral insulin preparation that is currently undergoing phase 3 clinical studies. The formulation, produced by Biocon, is a fast-acting insulin analogue that reaches maximum blood concentration after 20 minutes with the peak of action noted after 40 minutes. Absorption and action of the preparation is directly proportional to the dose administered [34] .
Transdermal application of insulin
Transdermal application is yet another interesting alternative to insulin injection. The stratum corneum, which forms the main barrier for the drug to be absorbed, limits the penetration of substances except for small lipophilic particles. Studies on the increase in skin permeability are being conducted. These studies use physicochemical methods such as iontophoresis (electric current application), ultrasound sonophoresis (use of ultrasound), microneedles (formation of microchannels in the stratum corneum), laser ablation, microdermabrasion (mechanical or chemical removal of the stratum corneum), and chemical enhancers changing the lipid structure of the stratum corneum and increasing its permeability [35, 36] .
Insulin patches
Insulin patches may be another alternative route of insulin administration. Insulin-loaded microemulsions are currently the most effective, although they are still in the preclinical phase. The patches contain 10% oleic acid, 38% aqueous phase, and 50% surfactant with 2% dimethyl sulfoxide [6, 36] .
Summary
Despite advances in the field of technology and the development of knowledge regarding the disease and the treatment methods, ever more effective tools are still searched for. Their aim is improvement in the quality of life and in glucose control as well as the improvement in patient compliance.
It is not certain what the future will bring. However, at present, trials for optimisation of insulin action and progressive automatisation of insulin pump therapy are in the most advanced trial phase.
Wstęp
Terapia insuliną to najskuteczniejszy sposób obniżania glikemii. Jest nieodzowna w leczeniu cukrzycy typu 1, niezbędna w wielu przypadkach cukrzycy typu 2. Od czasu odkrycia i pierwszego zastosowania insuliny minęło prawie 100 lat. Za nami lata badań, których celem było jak najwierniejsze odwzorowanie fizjologicznej odpowiedzi organizmu na wzrost glikemii i dążenie do optymalizacji insulinoterapii. Badania te pozwoliły na zastosowanie na szeroką skalę insulin ludzkich, a następnie szybko działających i bezszczytowych analogów insulin ludzkich. Na chwilę obecną, nadal podstawową drogą podaży insuliny, jest podskórne podanie przy użyciu penów oraz pomp insulinowych [1] . Insulina szybkodziałająca może być również podawana drogą dożylną, zwłaszcza u pacjentów hospitalizowanych w stanach znacznej hiperglikemii, takich jak cukrzycowa kwasica ketonowa, zespoły hiperglikemiczno-hipermolarne, czy leczenia zaburzeń gospodarki węglowodanowej u chorych przebywających na oddziałach intensywnej opieki medycznej oraz w okresie okołooperacyjnym na oddziałach zabiegowych [2] . Istnieją również próby zastosowania insuliny drogą PRACE POGLĄDOWE dożylną u pacjentów z cukrzycową bólową polineuropatią czuciowo-ruchową w celu złagodzenia nasilenia bólu i poprawy jakości życia u pacjentów z cukrzycą [3] .
Wraz z postępem technologicznym i zaawansowaniem wiedzy na temat cukrzycy, badania i poszukiwania w zakresie insulinoterapii wiodą w kilku kierunkach równocześnie: -optymalizacji parametrów działania insuliny, poprzez modyfikacje w zakresie farmakokinetyki (ultraszybkodziałające analogi insulin ludzkich, ultra długo działające analogi insulin ludzkich, czy też użycie czynników przyspieszających wchłanianie, takich jak ogrzewanie miejsca wkłucia, dodanie rekombinowanej ludzkiej hialuronidazy lub podanie insuliny śródskórne); -automatyzacji, czyli terapia pompowa w systemie zamkniętej pętli, nazywana "sztuczną trzustką"; -zmniejszenia inwazyjności metod podawania insuliny (ARIA -alternatywne drogi podania insuliny).
Optymalizacja parametrów działania insuliny
Fizjologicznie istnieją dwa sposoby wydzielana insuliny, pierwszy w odpowiedzi na posiłek oraz drugipodstawowy, niezależny od posiłku, który ma charakter pulsacyjny. Drogą układu wrotnego insulina trafia do wątroby, skąd około 50% jest dystrybuowane do tkanek obwodowych. Egzogenna podaż insuliny nie jest w stanie w pełni naśladować fizjologicznego charakteru wydzielania insuliny, gdyż podawana jest do tkanek obwodowych, co wpływa między innymi na nieprawidłowe działanie wątroby w zakresie gospodarki węglowodanowej u osób z endogennym niedoborem insuliny. O dynamice działania podawanych preparatów decydują ich farmakodynamiczne cechy oraz sposób ich podania.
Ultraszybkodziałające analogi insulin
Szybkodziałające analogi insuliny są dostępne na rynku od 1996 roku, jednak szczyt ich działania wciąż jest niewystarczający i nie pokrywa idealnie poposiłkowej hiperglikemii. Trwają badania nad ultra szybkodziałającą insuliną ludzką Linjeta (VIAject), a ich wyniki wskazują na to, że działa ona szybciej niż analog Lispro i dotychczas stosowane insuliny ludzkie, co znajduje odzwierciedlenie w skuteczniejszym obniżaniu poposiłkowej glikemii, bez zwiększonego ryzyka hipoglikemii. Linjeta jest preparatem złożonym z ludzkiej insuliny krótkodziałającej, kwasu etylenodiaminooctowego i cytrynowego. Taki skład, powoduje odłączenie jonów cynkowych od cząsteczek insuliny i zapobiega ich agregacji w heksamery, dzięki czemu insulina pozostaje w postaci monomerów i znacznie szybciej się wchłania [4, 5] . Porównując wpływ insuliny Linjeta, Lispro oraz insulin ludzkiej szybkodziałającej na glikemię poposiłkową u pacjentów z cukrzycą typu 1 uzyskano istotnie niższe wartości w grupie Linjeta (0-180 min; 157 ± 30 mg/dl; p = 0.002 vs. insulina ludzka szybkodziałająca) i w grupie Lispro (170 ± 42 mg/dl; p = 0.668 vs. insulina ludzka szybkodziałająca). Róż-nica między maksymalną i minimalną glikemią była mniejsza w przypadku Linjeta i wynosiła 70 ± 17 mg/dl, w porównaniu z insuliną ludzką szybkodziałającą (91 ± ± 33 mg/dL; p = 0,007 vs. Linjeta) i Lispro (89 ± 18 mg/dL; p = 0,011 vs. Linjeta) [4] . Przyspieszenie absorpcji insuliny próbowano osią-gnąć innymi metodami. Prowadzono badania kliniczne z urządzeniem InsuPatch ogrzewającym miejsce iniekcji i zwiększającym ukrwienie, co przyczyniało się do szybszego wchłaniania insuliny. Urządzenie to w domyśle mogłoby zostać zintegrowane z pompą insulinową i poprawić jej działanie [6] [7] [8] .
Kolejnym sposobem przyspieszenia absorpcji i działania insuliny jest dodanie rekombinowanej ludzkiej hialuronidazy do preparatu insuliny. Badania potwierdzają przyspieszenie wchłaniania insuliny z miejsca wstrzyknięcia oraz jej działanie, a co za tym idzie poprawę kontroli glikemii poposiłkowej, bez zwiększonego ryzyka hipoglikemii oraz wskazują na dobrą tolerancję i bezpieczeństwo tej metody [9] .
Do przyspieszenie absorpcji insuliny prowadzi również jej śródskórne podanie z wykorzystaniem mikroigły o długości 0,9 mm. W dwóch badaniach klinicznych przeprowadzonych u pacjentów w różnym wieku wykazano szybszy początek działania (o ok. 22 min) w porównaniu z insuliną podaną podskórnie, co tłumaczy się szybszą absorpcją insuliny z dobrze ukrwionej i o bogatym unaczynieniu limfatycznym warstwy brodawkowatej skóry [10] . Daje to nadzieję na poprawę precyzji działania pomp insulinowych w systemie zamkniętej pętli. Podanie śródskórne insuliny w ocenie pacjentów (analogowa skala natężenia bólu VAS) nie było bardziej bolesne, w porównaniu z podaniem podskórnym [10] .
Nowe insuliny bazowe
Degludec Poszukiwania w zakresie poprawy właściwości farmakodynamicznych insuliny zaowocowały stworzeniem nowego, ultradługodziałającego analogu insuliny ludzkiej Degludec. W styczniu 2013 roku, EMEA (Europejska Agencja Leków) dopuściła produkt Tresiba (insulina Degludec) i Ryzodeg (mieszanka insuliny Degludec i szybkodziałającego analogu insuliny ludzkiej Aspart) do obrotu w Unii Europejskiej [11] . Insulina bazowa Degludec po wstrzyknięciu podskórnym tworzy PRACE POGLĄDOWE rozpuszczalne multiheksamery, z których jest powoli wchłaniana do krwiobiegu. Czas działania przekracza 42 godziny w zakresie dawek terapeutycznych. Stan równowagi jest osiągany po 2-3 dniach podawania. Całkowite zmniejszenie stężenia glukozy po zastosowaniu Degludecu rośnie liniowo wraz ze zwiększeniem dawek [12] . Przeprowadzono 11 międzynarodowych, kontrolowanych, otwartych, randomizowanych, z grupami równoległymi, prowadzonych do osiągnięcia zakładanego celu, badań klinicznych trwających 26 lub 52 tygodnie, w których 4275 pacjentom podawano Degludec (1102 z cukrzycą typu 1 i 3173 z cukrzycą typu 2). Potwierdzono, że obniżenie HbA 1c było równoważne we wszystkich badaniach w odniesieniu do wszystkich produktów porównywanych (insulina Detemir i insulina Glargina) [12] [13] [14] . W metaanalizie obejmującej siedem badań prowadzonych do osiągnięcia zakłada-nego celu (treat to target) u pacjentów z cukrzycą typu 1 i typu 2 Degludec okazał się być skuteczniejszy pod względem mniejszej liczby potwierdzonych epizodów hipoglikemii wynikającej z leczenia i potwierdzonych hipoglikemii nocnych w porównaniu z insuliną bazową Glargina. Zmniejszenie liczby hipoglikemii zostało osiągnięte przy mniejszym średnim stężeniu glukozy w osoczu podczas podawania Degludecu, niż podczas podawania insuliny Glargina [15] .
Mieszanka insuliny Aspart i insuliny Degludec, podawana w cukrzycy typu 1 wraz z szybkodziałającą insuliną w porze innych posiłków, obniżała HbA 1c o 0,7%, a u pacjentów z cukrzycą typu 2 podawana samodzielnie lub w skojarzeniu z innymi lekami przeciwcukrzycowymi, nawet do 1,7% [16] [17] .
Glargina U300
Innym sposobem wydłużenia czasu działania insuliny było zastosowanie insuliny o wyższym stężeniu. Insulina Glargina U300 działała istotnie dłużej, w porównaniu z klasyczną Glarginą U100 oraz charakteryzowała się mniejszą zmiennością stężeń w surowicy. Wykazano, że czas działania Glargina U300 wynosi do 36 godzin po wstrzyknięciu do tkanki podskórnej. Bardziej stabilne uwalnianie insuliny Glargina U300 w porównaniu z insuliną Glargina U100 jest związane ze zmniejszeniem objętości wstrzyknięcia o 2/3, czego wynikiem jest mniejsza powierzchnia precypitatu [18] . Porównując Glarginę U100 i U300, uzyskano podobną efektywność i profil bezpieczeństwa, przy czym w grupie pacjentów stosujących insulinę U300 obserwowano mniejszy przyrost masy ciała oraz niższe ryzyko hipoglikemii [19] .
Pegylowana insulina Lispro
Obok insuliny Degludec oraz Glarginy U300 na uwagę zasługuje pegylowana insulina Lispro. Insulina ta powstaje w wyniku dołączenia łańcucha glikolu polietylenowego do cząsteczki insuliny Lispro. Pegylacja ma na celu wydłużenie czasu działania cząsteczki insuliny, zwiększenie jej właściwości hydrodynamicznych i spowolnienie absorpcji z tkanki podskórnej [20] . Tak zmodyfikowana insulina charakteryzuje się 24 h płaskim profilem działania. Wykazuje większą wątrobową niż obwodową aktywność, przez co naśladuje działanie endogennej insuliny. W badaniach klinicznych stwierdzono podobną lub lepszą kontrolę glikemii u pacjentów stosujących PegLispro w porównaniu z Glarginą, mniejszą zmnienność glikemii, zarówno w DM 1 jak i DM 2 oraz korzystny wpływ na masę ciała-utrata nawet 5% masy ciała w grupie leczonej PegLispro. Ryzyko hipoglikemii nocnych było istotnie mniejsze, przy nieco wyższym ryzyku hipoglikemii ogólnie (NS). Nie było konieczności zmiany dawki u pacjentów z zaburzeniami czynności nerek [20] . W badaniach III fazy porównując do insuliny Glargina, wykazano lepszy wpływ PegLispro na kontrolę glikemii, mniejszą zmienność glikemii redukcję całkowitej liczby hipoglikemii, szczególnie nocnych. Obserwowano jednak wzrost stężenia triglicerydów, podwyższenie stężenia aminotransferaz i zwiększenie zawartości tłuszczu w wątrobie [21] . Powyższe obserwacje stały się przyczyną zaprzestania dalszych badań dotyczących pegylowanej insulin Lispro i w grudniu 2015 roku firma EliLilly wstrzymała dalsze obserwacje.
Insuliny biozgodne
Z roku na rok rośnie sprzedaż insuliny na świecie, stąd coraz większe zainteresowanie firm farmaceutycznych wprowadzeniem do sprzedaży insulin biozgodnych (biosimilar insulins). Wiadomo, że produkcja białka, jakim jest insulina obejmuje kilka etapów i wszelkie nawet drobne zmiany w tej skomplikowanej procedurze mogą prowadzić do powstania produktów białkowych, różniących się od oryginału. Firma Eli Lilly i Merck prowadzą niezależnie badania kliniczne z użyciem biozgodnej Glarginy [22] .
Firma Biodel pracuje nad kolejną insuliną bazalną, tak zwaną BIOD-regulowaną insuliną bazową, która w swoim składzie zawiera zmodyfikowaną wersję insuliny Glarginy oraz ma zdolność mieszania preparatów o różnym czasie działania [22] .
Innym obiecującym preparatem insuliny jest BIOD--Smart Basal, preparat opracowany również przez firmę Biodel, który zawiera insulinę Glarginę, oksydazę glukozową i peroksydazę. W obecności glukozy i wyżej wymienionych enzymów powstaje kwas glukonowy, który obniża pH zawiesiny i zwiększa rozpuszczalność insuliny Glarginy, promując w ten sposób uwalnianie jej do obiegu [22] .
